ANDA 211219, held by Jubilant Generics. Eslicarbazepine Acetate.
As of Nov 16, 2026, ANDA 211219 (Eslicarbazepine Acetate), held by Jubilant Generics, was first approved by FDA on Aug 4, 2025, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 4, 2025 | Original application | Approved | None posted |
| Eslicarbazepine Acetate200MG · tablet;oral | Eslicarbazepine Acetate | Rx |
| Eslicarbazepine Acetate400MG · tablet;oral | Eslicarbazepine Acetate | Rx |
| Eslicarbazepine Acetate600MG · tablet;oral | Eslicarbazepine Acetate | Rx |
| Eslicarbazepine Acetate800MG · tablet;oral | Eslicarbazepine Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters